Entvin, Inc.

Entvin, Inc. is a San Francisco-based company specializing in regulatory AI solutions for the life sciences sector, focusing on enhancing FDA compliance processes and supporting pharmaceutical operations through innovative technology. Entvin, Inc. provides AI-driven regulatory solutions tailored for life sciences, enhancing compliance for pharmaceutical organizations.

Founded in 2022, the company has made one notable deal, raising INR 50. 000 mn in a funding round led by Y Combinator on March 28, 2025. The company's founder has a history of establishing other ventures, underscoring their expertise in the industry. Entvin specializes in providing advanced regulatory AI solutions tailored specifically for the life sciences sector.

Their core offerings include AI-driven tools designed to streamline FDA compliance processes for regulatory, medical affairs, and commercial teams. These products facilitate automated promotional material reviews, generate comprehensive claim libraries, and assist in the drafting of compliant labels by integrating real-time data analytics and automated tracking of regulatory updates. By employing AI technology, Entvin enables pharma professionals to enhance decision-making, ensure adherence to compliance standards, and drive innovation in their operations. The company serves a diverse customer base, including large biopharmaceutical corporations and mid-sized firms, across prominent geographical markets such as North America, Europe, and Asia-Pacific, thereby addressing the unique compliance challenges faced within these regions.

Entvin's revenue model is primarily built around subscription-based services that cater to its clients in the pharmaceutical and biotechnology industries. Clients engage with Entvin through various tiered subscription plans, which provide access to its suite of AI regulatory tools, including the Ads Promo AI and Labeling AI systems. These offerings are designed for businesses to optimize their regulatory processes and compliance measures through a direct-to-business model. Transaction structures typically involve annual or multi-year commitments, allowing clients to integrate these AI solutions into their operational frameworks efficiently.

The pricing plans are structured to reflect the scale of deployment and the specific needs of each client, ensuring that organizations can effectively leverage Entvin’s capabilities to enhance their compliance and promotional strategies. In March 2025, Entvin, Inc. raised INR 50. 000 mn in venture funding from Y Combinator.

The company will use this funding to enhance its artificial intelligence capabilities and accelerate customer acquisition among mid-to-large pharmaceutical companies globally. Entvin plans to launch new AI products designed to further streamline regulatory processes and compliance measures, while also targeting expansion into new geographical markets, including Latin America and the Middle East, by the end of 2025.